The Stock2Me Podcast

Stock2Me’s latest podcast features Dr. Alan Baratz, CEO of D-Wave Quantum Inc. (NYSE: QBTS), a leader in quantum computing systems, software and services that delivers customer value via practical quantum applications for computationally complex problems such as factory planning, resource allocation, job shop scheduling, labor allocation, vehicle routing, artificial intelligence, drug discovery, financial modeling and more. During the interview, Dr. Baratz discussed his journey to becoming the CEO of D-Wave, provided an introduction to quantum computing and offered perspectives on D-Wave’s leadership in driving the commercial adoption of this emerging technology. “Quantum computing is nothing more than using quantum mechanical effects – things like superposition, entanglement or tunneling – to solve computationally hard problems faster or better than they can be solved using classical computers. Quantum computing can be applied to both revolutionary applications, like developing designer drugs or global weather modeling, and evolutionary applications, like improving employee scheduling or autonomous vehicle routing on manufacturing plant floors. These evolutionary applications are problems that businesses are solving today; it's just that they're computationally so hard that businesses are using heuristics to try to come up with what they hope are ‘good enough’ solutions. With quantum computing, we're able to deliver better solutions faster to those problems.” “Quantum computing is crossing the chasm right now, from experimentation to enterprise usage. At D-Wave, we took a different approach to quantum computing from everybody else in the industry; we decided to start with annealing quantum computing. Annealing is a much easier technology to work with, it's easier to scale and much less sensitive to errors. That has allowed us to become commercial today. D-Wave is actually driving adoption in the market with real customers who have applications in production today, helping to benefit their business operations. Nobody else in the quantum industry can say that.” Please see full terms of use and disclaimers on the IBN website applicable to all content provided by IBN, wherever published or re-published: https://IBN.fm/Disclaimer

Stock2Me’s latest podcast features Dr. Alan Baratz, CEO of D-Wave Quantum Inc. (NYSE: QBTS), a leader in quantum computing systems, software and services that delivers customer value via practical quantum applications for computationally complex problems such as factory planning, resource allocation, job shop scheduling, labor allocation, vehicle routing, artificial intelligence, drug discovery, financial modeling and more. During the interview, Dr. Baratz discussed his journey to becoming the CEO of D-Wave, provided an introduction to quantum computing and offered perspectives on D-Wave’s leadership in driving the commercial adoption of this emerging technology. “Quantum computing is nothing more than using quantum mechanical effects – things like superposition, entanglement or tunneling – to solve computationally hard problems faster or better than they can be solved using classical computers. Quantum computing can be applied to both revolutionary applications, like developing designer drugs or global weather modeling, and evolutionary applications, like improving employee scheduling or autonomous vehicle routing on manufacturing plant floors. These evolutionary applications are problems that businesses are solving today; it's just that they're computationally so hard that businesses are using heuristics to try to come up with what they hope are ‘good enough’ solutions. With quantum computing, we're able to deliver better solutions faster to those problems.” “Quantum computing is crossing the chasm right now, from experimentation to enterprise usage. At D-Wave, we took a different approach to quantum computing from everybody else in the industry; we decided to start with annealing quantum computing. Annealing is a much easier technology to work with, it's easier to scale and much less sensitive to errors. That has allowed us to become commercial today. D-Wave is actually driving adoption in the market with real customers who have applications in production today, helping to benefit their business operations. Nobody else in the quantum industry can say that.” Please see full terms of use and disclaimers on the IBN website applicable to all content provided by IBN, wherever published or re-published: https://IBN.fm/Disclaimer

Stock2Me’s latest podcast features Joel Fruendt, President and CEO of SenesTech Inc. (NASDAQ: SNES), the leader in fertility control to manage animal pest populations. To begin the interview, Fruendt provided an introduction to SenesTech’s business model and operating markets. “SenesTech is a biotech and life sciences company that develops, patents and commercializes product formulations for fertility control of animal pests. Our mission is improving the health of our world by humanely managing animal pest populations through fertility control,” Fruendt said. “We're addressing one of the world's oldest and most challenging problems, and that's rodent control. We're doing this through a completely different way than has ever been done before by addressing the root cause of the problem, which is reproduction.”

Stock2Me’s latest podcast features Joel Fruendt, President and CEO of SenesTech Inc. (NASDAQ: SNES), the leader in fertility control to manage animal pest populations. To begin the interview, Fruendt provided an introduction to SenesTech’s business model and operating markets. “SenesTech is a biotech and life sciences company that develops, patents and commercializes product formulations for fertility control of animal pests. Our mission is improving the health of our world by humanely managing animal pest populations through fertility control,” Fruendt said. “We're addressing one of the world's oldest and most challenging problems, and that's rodent control. We're doing this through a completely different way than has ever been done before by addressing the root cause of the problem, which is reproduction.”

Stock2Me’s latest podcast features M.E. Tuthill, a financial writer and journalist and author of Repo-Madness: A Simpleton’s Guide to the Street’s Wicked Ways, a book aiming to blow the lid off what has come to be known as the shadow banking system. To begin the interview, Tuthill discussed her background. “I was born and raised outside of Boston, Massachusetts, and I spent the earlier part of my career in broadcasting as a radio journalist. After 10 years of that… I was ready for a change. I decided to take a big leap – and I mean big… I decided to become a financial advisor,” Tuthill said. “I did that for 13 years, and it was a really good experience. I learned a lot about money. Ironically, though, I was in all these brokerage firms, and I knew nothing about what I’m now writing about, which is the huge market and the financial system.” “After 13 years, I’d had enough of that… I got a position as a financial writer at iMoneyNet… I wrote articles about money market funds. When I first got the job I thought, ‘Oh this is great, I’ve got a 9-to-5 and a steady paycheck,’ but money market funds weren’t really that exciting to write about. When the financial crisis hit, everything changed. Those funds had such an integral role in what happened. For the next nine years after that happened, I wrote every week and every day about the money market funds and the shadow banking system in general. I got addicted to it; I got hooked on it.” Tuthill then provided an introduction to Repo-Madness: A Simpleton’s Guide to the Street’s Wicked Ways by discussing the concept of shadow banking.

Stock2Me’s latest podcast features M.E. Tuthill, a financial writer and journalist and author of Repo-Madness: A Simpleton’s Guide to the Street’s Wicked Ways, a book aiming to blow the lid off what has come to be known as the shadow banking system. To begin the interview, Tuthill discussed her background. “I was born and raised outside of Boston, Massachusetts, and I spent the earlier part of my career in broadcasting as a radio journalist. After 10 years of that… I was ready for a change. I decided to take a big leap – and I mean big… I decided to become a financial advisor,” Tuthill said. “I did that for 13 years, and it was a really good experience. I learned a lot about money. Ironically, though, I was in all these brokerage firms, and I knew nothing about what I’m now writing about, which is the huge market and the financial system.” “After 13 years, I’d had enough of that… I got a position as a financial writer at iMoneyNet… I wrote articles about money market funds. When I first got the job I thought, ‘Oh this is great, I’ve got a 9-to-5 and a steady paycheck,’ but money market funds weren’t really that exciting to write about. When the financial crisis hit, everything changed. Those funds had such an integral role in what happened. For the next nine years after that happened, I wrote every week and every day about the money market funds and the shadow banking system in general. I got addicted to it; I got hooked on it.” Tuthill then provided an introduction to Repo-Madness: A Simpleton’s Guide to the Street’s Wicked Ways by discussing the concept of shadow banking.

Stock2Me’s latest podcast features the return of David Jemmett, CEO and Founder of CISO Global Inc. (NASDAQ: CISO), an industry leader in cybersecurity and compliance services. Throughout the interview, Jemmett discussed the current state of the cybersecurity industry and CISO’s expanding position within it. “Here’s a rhetorical question: Are we doing cybersecurity correctly today? No. With $6 trillion lost last year, we only spent $282 billion; we have to do something to catch up with or surpass the bad guys. We have to come up with new, innovative methods, and, with a talent shortage of four million jobs, we also have to train and enhance what we’re doing to protect not only our customers, but ourselves,” Jemmett said. “Since CISO was incepted, we self-funded ourselves through the OTC and bought 12 companies on a global basis. In January 2022, we uplisted to Nasdaq. Since then, we’ve acquired a total of 18 organizations, stock-for-stock, and brought some of the brightest stars in cybersecurity and compliance spanning three separate continents to our organization.” Join IBN’s Stuart Smith and David Jemmett to learn more about the company’s recent milestones and explore the ways CISO ensures compliance with evolving industry standards and regulations.

Stock2Me’s latest podcast features the return of David Jemmett, CEO and Founder of CISO Global Inc. (NASDAQ: CISO), an industry leader in cybersecurity and compliance services. Throughout the interview, Jemmett discussed the current state of the cybersecurity industry and CISO’s expanding position within it. “Here’s a rhetorical question: Are we doing cybersecurity correctly today? No. With $6 trillion lost last year, we only spent $282 billion; we have to do something to catch up with or surpass the bad guys. We have to come up with new, innovative methods, and, with a talent shortage of four million jobs, we also have to train and enhance what we’re doing to protect not only our customers, but ourselves,” Jemmett said. “Since CISO was incepted, we self-funded ourselves through the OTC and bought 12 companies on a global basis. In January 2022, we uplisted to Nasdaq. Since then, we’ve acquired a total of 18 organizations, stock-for-stock, and brought some of the brightest stars in cybersecurity and compliance spanning three separate continents to our organization.” Join IBN’s Stuart Smith and David Jemmett to learn more about the company’s recent milestones and explore the ways CISO ensures compliance with evolving industry standards and regulations.

Stock2Me’s latest podcast features Rod Turner, CEO and Founder of Manhattan Street Capital, the premier growth capital platform for midsize and startup companies. Throughout the interview, Turner discussed his professional background – from his time as an engineer to his successful track record as an entrepreneur – before examining why he founded Manhattan Street Capital. “In March 2015, Reg A+ was announced, and it went effective in late June. When I read the regulation, I was shocked and impressed by how well-written it is,” Turner said. “Having raised money and invested money in startup companies over so many years and such a large portion of my business life, I’m aware of how the current lending climate for capital raising was limiting lots of great companies that could otherwise justify and deploy growth capital successfully and make public offerings successfully. Reg A+ provided a phenomenally great way to up the ante and improve the situation… The timing was great, so I decided to found Manhattan Street Capital in May 2015 – about a month before Reg A+ became effective. We were the first Reg A+-focused offering platform in what is essentially crowd investing. I believe that Reg A+, when it hits stride, will be a very, very large segment of the capital-raising industry.” Join IBN’s Stuart Smith and Rod Turner to learn more about the rapid growth of the Reg A+ space and the trends guiding the online capital formation business in 2023.

Stock2Me’s latest podcast features Rod Turner, CEO and Founder of Manhattan Street Capital, the premier growth capital platform for midsize and startup companies. Throughout the interview, Turner discussed his professional background – from his time as an engineer to his successful track record as an entrepreneur – before examining why he founded Manhattan Street Capital. “In March 2015, Reg A+ was announced, and it went effective in late June. When I read the regulation, I was shocked and impressed by how well-written it is,” Turner said. “Having raised money and invested money in startup companies over so many years and such a large portion of my business life, I’m aware of how the current lending climate for capital raising was limiting lots of great companies that could otherwise justify and deploy growth capital successfully and make public offerings successfully. Reg A+ provided a phenomenally great way to up the ante and improve the situation… The timing was great, so I decided to found Manhattan Street Capital in May 2015 – about a month before Reg A+ became effective. We were the first Reg A+-focused offering platform in what is essentially crowd investing. I believe that Reg A+, when it hits stride, will be a very, very large segment of the capital-raising industry.” Join IBN’s Stuart Smith and Rod Turner to learn more about the rapid growth of the Reg A+ space and the trends guiding the online capital formation business in 2023.

Stock2Me’s latest podcast features David Jemmett, CEO and Founder of Cerberus Cyber Sentinel Corp. (NASDAQ: CISO) (“CISO Global” or the “Company”), an industry leader in cybersecurity and compliance services. Throughout the interview, Jemmett discussed the core values and mission of Cerberus Sentinel. “Cerberus Sentinel was founded at a period of time when there were 800,000 job openings in cyber. There’s been a zero jobless rate since 2011. This year alone there are four million job openings [in cyber] globally,” Jemmett said. “A lot of my friends and coworkers have started cybersecurity companies in the past, but they were very verticalized – training, gap analysis, compliance or SOC services… At Cerberus Sentinel, we help our clients find their cyber issues, remediate them and keep on top of them. Cybersecurity is a journey; it’s not an endpoint. We’ll continue to work on the evolving threat matrix with our customers to help them keep improving.” Join IBN’s Stuart Smith and David Jemmett to learn more about the company’s unique offerings in the cyber space and how they differentiate Cerberus Sentinel from the competition.

Stock2Me’s latest podcast features Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious diseases and autoimmune diseases. In this podcast episode, Reichman introduced the history of BiondVax leading up to his appointment as CEO before discussing the company’s recent development efforts focused on innovative nanosized antibody (NanoAb) therapies addressing diseases underserved by current treatments and with large and growing markets. “BiondVax is a biotechnology company focused on research and development. It is located in Jerusalem, Israel. It was founded about 17 years ago by an entrepreneur who took a spinoff from the Weizmann Institute of Science in Israel with a mission to develop a universal influenza vaccine,” Reichman said. “The vaccine was developed in the laboratory of Professor Ruth Arnon, a world-renowned professor and researcher mostly known for co-developing Copaxone, the multiple sclerosis drug marketed by Teva Pharmaceuticals. The universal influenza vaccine was then developed by BiondVax throughout the next 15 years, covering Preclinical, Phase I and multiple Phase II trials before ending up with a Phase III – the biggest Phase III ever conducted by an Israeli pharma company, with 12,400 participants spanning seven countries. The latest installment of The Stock2Me Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers and the growing IBN Podcast Series. For more than 15 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies. To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

Stock2Me’s latest podcast features Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious diseases and autoimmune diseases. In this podcast episode, Reichman introduced the history of BiondVax leading up to his appointment as CEO before discussing the company’s recent development efforts focused on innovative nanosized antibody (NanoAb) therapies addressing diseases underserved by current treatments and with large and growing markets. “BiondVax is a biotechnology company focused on research and development. It is located in Jerusalem, Israel. It was founded about 17 years ago by an entrepreneur who took a spinoff from the Weizmann Institute of Science in Israel with a mission to develop a universal influenza vaccine,” Reichman said. “The vaccine was developed in the laboratory of Professor Ruth Arnon, a world-renowned professor and researcher mostly known for co-developing Copaxone, the multiple sclerosis drug marketed by Teva Pharmaceuticals. The universal influenza vaccine was then developed by BiondVax throughout the next 15 years, covering Preclinical, Phase I and multiple Phase II trials before ending up with a Phase III – the biggest Phase III ever conducted by an Israeli pharma company, with 12,400 participants spanning seven countries. The latest installment of The Stock2Me Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers and the growing IBN Podcast Series. For more than 15 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies. To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

Stock2Me’s latest podcast features two-time Olympic gold medalist Abby Wambach speaking on behalf of Odyssey Health Inc. (OTC: ODYY), a medical technology company developing a drug/device combination intended to treat concussion. Wambach is a member of Odyssey’s sports advisory board, which aims to support the company’s efforts to enhance public awareness of traumatic brain injuries and concussions, as well as the need for an FDA-approved therapy. Throughout the interview, Wambach discussed her soccer career and how concerns about brain health led her to team with Odyssey Health. “I had a unique, long career playing for the Women’s National Team. I played in many Olympics and World Cups, won a bunch of golds and, in my retirement (I’ve been retired for six years), I’ve had a lot of time to reflect on the time that I played,” Wambach said. “I played soccer for 30 years, and one of the biggest concerns that I have going into the rest of my life is my brain health and wellness. Of course, a lot of us only think of concussions and CTE as it relates to NFL football, but the reality is that brain trauma happens in every sport.”

Stock2Me’s latest podcast features two-time Olympic gold medalist Abby Wambach speaking on behalf of Odyssey Health Inc. (OTC: ODYY), a medical technology company developing a drug/device combination intended to treat concussion. Wambach is a member of Odyssey’s sports advisory board, which aims to support the company’s efforts to enhance public awareness of traumatic brain injuries and concussions, as well as the need for an FDA-approved therapy. Throughout the interview, Wambach discussed her soccer career and how concerns about brain health led her to team with Odyssey Health. “I had a unique, long career playing for the Women’s National Team. I played in many Olympics and World Cups, won a bunch of golds and, in my retirement (I’ve been retired for six years), I’ve had a lot of time to reflect on the time that I played,” Wambach said. “I played soccer for 30 years, and one of the biggest concerns that I have going into the rest of my life is my brain health and wellness. Of course, a lot of us only think of concussions and CTE as it relates to NFL football, but the reality is that brain trauma happens in every sport.”

Stock2Me’s latest podcast features the return of Ian Clifford, CEO of FuelPositive Corp. (TSX.V: NHHH) (OTCQB: NHHHF), a growth stage company committed to providing commercially viable and sustainable “cradle to cradle” clean technology solutions, including green ammonia (NH3), for use across a broad spectrum of industries and applications. Throughout the interview, Clifford discussed FuelPositive’s rapid development throughout 2021 and early in 2022 as it works to change the landscape surrounding ammonia production, with a focus on sustainability. “2021 was a kick-off year for us. It was incredible the amount of growth that we were able to attain during the year,” Clifford said. “If you go back to January 2021, we formally became FuelPositive. A couple of months later, we acquired our core technology, which of course is a modular and scalable green ammonia production technology. We’re now right in the process of initial commercialization of demonstration systems… Our focus is very much on looking at technologies that are ready to commercialize today. We’re building now as we speak upon our core technology with add-on and very accretive intellectual property that is improving dramatically upon our core systems.”

Stock2Me’s latest podcast features the return of Ian Clifford, CEO of FuelPositive Corp. (TSX.V: NHHH) (OTCQB: NHHHF), a growth stage company committed to providing commercially viable and sustainable “cradle to cradle” clean technology solutions, including green ammonia (NH3), for use across a broad spectrum of industries and applications. Throughout the interview, Clifford discussed FuelPositive’s rapid development throughout 2021 and early in 2022 as it works to change the landscape surrounding ammonia production, with a focus on sustainability. “2021 was a kick-off year for us. It was incredible the amount of growth that we were able to attain during the year,” Clifford said. “If you go back to January 2021, we formally became FuelPositive. A couple of months later, we acquired our core technology, which of course is a modular and scalable green ammonia production technology. We’re now right in the process of initial commercialization of demonstration systems… Our focus is very much on looking at technologies that are ready to commercialize today. We’re building now as we speak upon our core technology with add-on and very accretive intellectual property that is improving dramatically upon our core systems.”

Stock2Me’s latest podcast features Chris Bunka, Chairman & CEO of Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms. To begin the interview, Bunka provided a summary of Lexaria’s business model, which is focused on leveraging the company’s proprietary DehydraTECH™ drug delivery technology. “[Lexaria has] developed a drug delivery technology that’s quite unique,” Bunka said. “What our technology does is it allows people to swallow any number of various drugs or active pharmaceutical ingredients (APIs) and basically allow a larger proportion of the drug to… get into the bloodstream and reach the site of action. That is what our technology is focused on, and, because we’re so good at it, we’re actually seeing applications in all sorts of different business sectors, be it cannabidiol, nicotine for oral delivery, antiviral drugs and others… We do not sell any drugs ourselves, but we do sell or ‘rent’ our technology.”

Stock2Me’s latest podcast features Chris Bunka, Chairman & CEO of Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms. To begin the interview, Bunka provided a summary of Lexaria’s business model, which is focused on leveraging the company’s proprietary DehydraTECH™ drug delivery technology. “[Lexaria has] developed a drug delivery technology that’s quite unique,” Bunka said. “What our technology does is it allows people to swallow any number of various drugs or active pharmaceutical ingredients (APIs) and basically allow a larger proportion of the drug to… get into the bloodstream and reach the site of action. That is what our technology is focused on, and, because we’re so good at it, we’re actually seeing applications in all sorts of different business sectors, be it cannabidiol, nicotine for oral delivery, antiviral drugs and others… We do not sell any drugs ourselves, but we do sell or ‘rent’ our technology.”

Stock2Me’s latest podcast features Ian Clifford, CEO of FuelPositive Corp. (TSX.V: NHHH) (OTCQB: NHHHF), a growth stage company focused on manufacturing, licensing, partnership and acquisition opportunities building upon various technological achievements. Throughout the interview, Clifford discussed FuelPositive’s innovative carbon-free ammonia technology and its potential to change the energy landscape, both across Canada and around the world. “We have purchased, back in April 2021, a cutting-edge technology that is designed to produce carbon-free ammonia, or carbon-free NH3 as it’s also known, in a proprietary, environmentally sound and economically viable process,” Clifford said. “This technology… allows for the production of ammonia in a scalable and modular fashion. That means that we can set up our systems to produce carbon-free ammonia where it’s needed and when it’s needed, which is a very, very significant departure from the way that ammonia is produced today… Ammonia today… is one of the most carbon-intense processes on the planet. Our system is entirely carbon-free.”